Oramed Pharmaceuticals ORMP Institutional Ownership

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has 85 institutional investors that have filed 13F reports for the period ending June 2026.

• These investors collectively held 36.4% of Oramed Pharmaceuticals's outstanding shares in June 2026, up from 32.5% in March 2026.
• Their total shares held in ORMP increased 14.01% quarter over quarter, and separately, investors owning Oramed Pharmaceuticals increased 84.78% from a year ago.
• During the quarter, 50 of these 85 funds increased positions in ORMP, 19 reduced exposure, and 16 held steady.
• Altogether, these fund groups held 14.96Mn shares in ORMP by June 2026, up by 1.84Mn shares quarter on quarter, and up 7.7Mn shares year over year.
• As of June 30, 2026, Aquamarine Financial (Cayman) Ltd held the largest stake in Oramed Pharmaceuticals with 2.51Mn shares, accounting for 6.12% of total shares outstanding.
• The most significant purchases of ORMP for the quarter ending June 2026 came from BlackRock, Inc. (1.52Mn), GEODE CAPITAL MANAGEMENT, LLC (476.41K), Aquamarine Financial (Cayman) Ltd (399.86K), Gem Investment Advisors, LLC (358.73K), Goldman Sachs Group Inc (253.29K).
• The largest sales of ORMP for the quarter ending June 2026 came from BML Capital Management, LLC (2.3Mn), MARSHALL WACE, LLP (157.66K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (113.92K), RITHOLTZ WEALTH MANAGEMENT (71.13K), CITADEL ADVISORS LLC (57.06K).
• Per Business Quant, the top 10 investors in ORMP for the quarter ending June 2026 include Aquamarine Financial (Cayman) Ltd (2.51Mn), Gem Investment Advisors, LLC (2.0Mn), MERCER GLOBAL ADVISORS INC /ADV (1.91Mn), BlackRock, Inc. (1.61Mn), Murchinson Ltd. (1.29Mn), BML Capital Management, LLC (866.27K), BOOTHBAY FUND MANAGEMENT, LLC (578.64K), GEODE CAPITAL MANAGEMENT, LLC (500.69K), Goldman Sachs Group Inc (253.29K), State Street Corp (242.1K).